BR112018071654A2 - polimorfismo de cristal do ativador de canais kcnq2-5 - Google Patents
polimorfismo de cristal do ativador de canais kcnq2-5Info
- Publication number
- BR112018071654A2 BR112018071654A2 BR112018071654-5A BR112018071654A BR112018071654A2 BR 112018071654 A2 BR112018071654 A2 BR 112018071654A2 BR 112018071654 A BR112018071654 A BR 112018071654A BR 112018071654 A2 BR112018071654 A2 BR 112018071654A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystal
- kcnq2
- polymorphism
- crystalline
- channel activator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
o polimorfismo cristalino pode existir em um composto cristalino. no caso em que existe polimorfismo de cristal, dependendo da forma do cristal, solubilidade, taxa de dissolução, estabilidade contra o calor, luz, umidade, etc. ou algo parecido é diferente. por conseguinte, na produção de um produto farmacêutico, é uma tarefa muito importante selecionar uma forma de cristal de uma substância farmacológica mais adequada para uma indicação de doença e uma forma de dosagem. a presente invenção se refere a novas formas cristalinas (cristal a, cristal w e cristal hidrato (cristal h)) de um composto i tendo uma forte ação de abertura em relação aos canais kcnq2-5.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016086239 | 2016-04-22 | ||
| JP2016-086239 | 2016-04-22 | ||
| PCT/JP2017/016109 WO2017183725A1 (ja) | 2016-04-22 | 2017-04-21 | Ｋｃｎｑ２～５チャネル活性化剤の結晶多形 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071654A2 true BR112018071654A2 (pt) | 2019-02-19 |
Family
ID=60116201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071654-5A BR112018071654A2 (pt) | 2016-04-22 | 2017-04-21 | polimorfismo de cristal do ativador de canais kcnq2-5 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190135755A1 (pt) |
| EP (1) | EP3447047A1 (pt) |
| JP (1) | JP6265313B1 (pt) |
| KR (1) | KR20180135448A (pt) |
| CN (1) | CN109071441A (pt) |
| AU (1) | AU2017254257A1 (pt) |
| BR (1) | BR112018071654A2 (pt) |
| CA (1) | CA3021624A1 (pt) |
| IL (1) | IL262439A (pt) |
| MX (1) | MX2018012898A (pt) |
| PH (1) | PH12018502228A1 (pt) |
| RU (1) | RU2018136892A (pt) |
| SG (1) | SG11201809184VA (pt) |
| WO (1) | WO2017183725A1 (pt) |
| ZA (1) | ZA201807006B (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA89503C2 (uk) * | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| SI2888233T1 (sl) * | 2012-04-18 | 2016-12-30 | Gruenenthal Gmbh | Substituirani 6-amino-nikotinamidi, ki nosijo skupino, ki vsebuje OH, kot modulatorji KCNQ2/3 |
| JP2016508960A (ja) * | 2012-11-28 | 2016-03-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｋｃｎｑ２／３モジュレーターとしての特定のカルボキサミド |
| CA2965467A1 (en) * | 2014-10-24 | 2016-04-28 | Ono Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
-
2017
- 2017-04-21 WO PCT/JP2017/016109 patent/WO2017183725A1/ja active Application Filing
- 2017-04-21 MX MX2018012898A patent/MX2018012898A/es unknown
- 2017-04-21 US US16/095,370 patent/US20190135755A1/en not_active Abandoned
- 2017-04-21 AU AU2017254257A patent/AU2017254257A1/en not_active Abandoned
- 2017-04-21 CA CA3021624A patent/CA3021624A1/en not_active Abandoned
- 2017-04-21 RU RU2018136892A patent/RU2018136892A/ru not_active Application Discontinuation
- 2017-04-21 BR BR112018071654-5A patent/BR112018071654A2/pt not_active Application Discontinuation
- 2017-04-21 KR KR1020187030081A patent/KR20180135448A/ko unknown
- 2017-04-21 JP JP2017546923A patent/JP6265313B1/ja not_active Expired - Fee Related
- 2017-04-21 EP EP17786062.4A patent/EP3447047A1/en not_active Withdrawn
- 2017-04-21 CN CN201780025011.7A patent/CN109071441A/zh active Pending
- 2017-04-21 SG SG11201809184VA patent/SG11201809184VA/en unknown
-
2018
- 2018-10-17 IL IL262439A patent/IL262439A/en unknown
- 2018-10-18 PH PH12018502228A patent/PH12018502228A1/en unknown
- 2018-10-19 ZA ZA2018/07006A patent/ZA201807006B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201807006B (en) | 2019-07-31 |
| RU2018136892A (ru) | 2020-05-22 |
| EP3447047A4 (en) | 2019-02-27 |
| JPWO2017183725A1 (ja) | 2018-04-26 |
| CA3021624A1 (en) | 2017-10-26 |
| EP3447047A1 (en) | 2019-02-27 |
| WO2017183725A1 (ja) | 2017-10-26 |
| PH12018502228A1 (en) | 2019-07-08 |
| CN109071441A (zh) | 2018-12-21 |
| KR20180135448A (ko) | 2018-12-20 |
| IL262439A (en) | 2018-12-31 |
| AU2017254257A1 (en) | 2018-11-15 |
| JP6265313B1 (ja) | 2018-01-24 |
| US20190135755A1 (en) | 2019-05-09 |
| MX2018012898A (es) | 2019-01-30 |
| SG11201809184VA (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| CY1120662T1 (el) | Παραγωγα πυρρολαμιδιου υποκατεστημενου γλυοξαμιδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β | |
| CY1123801T1 (el) | Παραγωγα αρωματικου σουλφοναμιδιου | |
| BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
| UY37271A (es) | Composiciones nasales de cannabinoides | |
| CL2018000249A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| CO2017006788A2 (es) | Forma de dosificación que incluye una solución sólida de drogas amorfas | |
| BR112017011644A2 (pt) | métodos e composições de ativação da ligase parkina | |
| BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112016025317A2 (pt) | conjunto, dispositivo e método para a análise imunocromatográfica | |
| CY1122113T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| BR112015008175A2 (pt) | modo e dispositivo para fotografia com lapso de tempo | |
| CL2020001226A1 (es) | Proceso para preparar tapinarof. | |
| UY35344A (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
| BR112017021283A2 (pt) | comprimido de ribociclib | |
| CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
| BR112017028218A2 (pt) | ?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos? | |
| BR112022010899A2 (pt) | Produto oral com componente dissolúvel | |
| BR112017013253A2 (pt) | comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes | |
| CY1126058T1 (el) | Αγωγη μιτοχονδριακων παθησεων | |
| UY36595A (es) | Formulación compleja farmacéutica que comprende amlodipina, losartán y clortalidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |